Dr. James Berenson discusses the importance of using maintenance therapies with limited short- or long-term side effects, in particular avoiding therapies that have long-term toxicity. Dr. Berenson expresses his excitement that within the next few years there is hope...
New drugs provide powerful options, but little consensus on standard treatments New York—There is a profound disagreement over whether early stem cell transplant (SCT) should still be characterized as a standard early intervention for multiple myeloma (MM), even in...
Posted By Navneet Ramesh and Maike Haehle on the Myeloma Beacon on Aug 31, 2013 2:01 Researchers recently reported updated survival rates for multiple myeloma patients in the United States. The results show that survival has improved steadily – and markedly –...
